Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
YUVA-GT-F801
- Development stage
- Phase 1
- Lead developer
- Shenzhen Geno-Immune Medical Institute
- Modality
- Stem Cell Therapies → Cell Therapies, Gene Therapies
- Administration
- Intravenous
01
Overview
YUVA-GT-F801 is a gene therapy product for hemophilia A that uses lentiviral vectors to deliver a functional gene for human clotting factor VIII into patients' autologous hematopoietic stem cells and mesenchymal stem cells, which are then infused back into the patient.
02
Targets
F8 (Coagulation Factor VIIIa)
Beyond the preview
Go deeper on YUVA-GT-F801.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on YUVA-GT-F801.